4 results match your criteria: "University of Rochestergrid.16416.34[Affiliation]"

Article Synopsis
  • The CDC's Emerging Infections Program studied carbapenem-resistant Pseudomonas aeruginosa (CRPA) in the U.S. from 2016 to 2018 through population and laboratory surveillance, collecting 1,019 isolates for analysis.
  • The study found high genetic diversity among the strains, with 336 different sequence types, and the majority (87.1%) of isolates exhibited mutations in the porin OprD, linked to carbapenem resistance.
  • While only a small percentage contained carbapenemase genes, many had non-carbapenemase β-lactamase genes, indicating that other resistance mechanisms also play a significant role in the spread of CRPA in the U.S.
View Article and Find Full Text PDF

Influenza A viruses (IAV) remain emerging threats to human public health. Live-attenuated influenza vaccines (LAIV) are one of the most effective prophylactic options to prevent disease caused by influenza infections. However, licensed LAIV remain restricted for use in 2- to 49-year-old healthy and nonpregnant people.

View Article and Find Full Text PDF

Streptococcus mutans promotes a tooth-damaging dysbiosis in the oral microbiota because it can form biofilms and survive acid stress better than most of its ecological competitors, which are typically health associated. Many of these commensals produce hydrogen peroxide; therefore, S. mutans must manage both oxidative stress and acid stress with coordinated and complex physiological responses.

View Article and Find Full Text PDF

Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart.

View Article and Find Full Text PDF